PTX prescient therapeutics limited

Ann: First Patient dosed for PTX-100 Phase 2a Study, page-8

  1. 2,111 Posts.
    lightbulb Created with Sketch. 823
    Slowly eating into the sellers and going up on this milestone.
    I am expecting the price to be much higher.
    At least James is getting out there and trying to tell the world about PTX.


    Prescient Therapeutics (ASX: PTX) is pleased to announce the first patient has been dosed in its Phase 2a clinical study of PTX-100.

    This announcement, and its significance in advancing PTX-100 towards commercialisation, will be discussed in a live investor briefing on Thursday 29th May at 12pm (AEST). Register here or request a recording.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.0¢
Change
0.002(4.17%)
Mkt cap ! $40.26M
Open High Low Value Volume
4.8¢ 5.3¢ 4.7¢ $52.6K 1.062M

Buyers (Bids)

No. Vol. Price($)
5 472791 4.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.0¢ 286543 2
View Market Depth
Last trade - 15.52pm 20/06/2025 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.